Table 3. Estimates of PPSV23 and PCV13 vaccine effectiveness (VE) against invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia.
| VE against invasive pneumococcal disease (%) [4, 5, 8] | ||||||
| PPSV23 | PCV13 | |||||
| Years post-vaccination | < 65 years | 65–74 years | ≥ 75 years | < 65 years | 65–74 years | ≥ 75 years |
| Base (low-high) | Base (low-high) | Base (low-high) | Base (low-high) | Base (low-high) | Base (low-high) | |
| 1 | 95.3 (92.0–95.0) | 82.0 (69.0–90.0) | 68.7 (23.0–85.0) | 79.4 (61.7–88.2) | 75.0 (52.9–83.8) | 62.8 (17.6–19.2) |
| 3 | 91.2 (85.1–94.5) | 74.8 (57.5–83.0) | 54.3 (0–83.5) | 70.6 (48.5–83.8) | 70.6 (39.7–79.4) | 51.2 (13.2–75.0) |
| 5 | 87.2 (76.0–90.0) | 59.5 (35.1–80.0) | 32.8 (0–75.0) | 61.8 (44.2–79.4) | 61.8 (26.5–76.8) | 34.1 (8.8–72.5) |
| 7 | 61.5 (46.2–75.0) | 33.8 (15.0–48.0) | 10.3 (0–30.0) | 52.9 (33.2–70.8) | 52.9 (19.9–68.4) | 16.0 (6.6–64.6) |
| 10 | 20.5 (0–30.0) | 0 (0–10.0) | 0 (0–10.0) | 44.1 (35.2–70.6) | 44.1 (13.2–60.0) | 0 (0–56.7) |
| 15 | 0 (0–20.0) | 0 (0–10.0) | 0 (0–10.0) | 39.7 (0–52.9) | 29.1 (0–52.9) | 0 (0–50.0) |
| VE against non-bacteremic pneumococcal pneumonia (%) [3–5, 8] | ||||||
| PPSV23 | PCV13 | |||||
| Years post-vaccination | < 65 years | 65–74 years | ≥ 75 years | < 65 years | 65–74 years | ≥ 75 years |
| Base (low-high) | Base (low-high) | Base (low-high) | Base (low-high) | Base (low-high) | Base (low-high) | |
| 1 | - | - | - | 52.0 (37.1–52.6) | 45.0 (31.8–50.3) | 37.7 (26.6–42.1) |
| 3 | - | - | - | 46.6 (29.1–50.5) | 42.4 (23.8–47.6) | 30.7 (17.3–34.6) |
| 5 | - | - | - | 39.9 (26.5–47.9) | 37.1 (15.9–46.1) | 20.4 (8.8–25.4) |
| 7 | - | - | - | 34.2 (19.8–42.6) | 31.8 (11.9–41.0) | 9.6 (3.6–12.4) |
| 10 | - | - | - | 28.6 (21.1–42.5) | 26.5 (7.9–36.0) | 0 (0–4.1) |
| 15 | - | - | - | 25.9 (0–31.8) | 17.5 (0–31.8) | 0 (0–4.1) |
PPSV23, 23-valent pneumococcal polysaccharide vaccine; PCV13, 13-valent pneumococcal conjugate vaccine